CHB患者血清miRNA-122和miRNA-155检测的价值

Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B

目的探讨慢性乙型肝炎(CHB)患者血清微小RNA(miRNA)-122和miRNA-155水平与乙型肝炎病毒(HBV)复制情况、抗病毒治疗及耐药基因突变等的关系。方法检测35例CHB患者和24名体检健康者的血清miRNA-122、miRNA-155、HBV DNA载量、乙型肝炎血清学标志物[乙型肝炎表面抗原(HBsAg)、乙型肝炎表面抗体(HBsAb)、乙型肝炎e抗原(HBeAg)、乙型肝炎e抗体(HBeAb)、乙型肝炎核心抗体(HBcAb)]、丙氨酸氨基转移酶(ALT)、HBV耐药基因突变、HBV基因型等指标。采用Spearman相关分析评估各项目间的相关性。结果CHB组血清miRNA-122相对表达量明显高于正常对照组(P<0.05),血清miRNA-155表达量明显低于正常对照组(P<0.05)。根据是否使用核苷类药物进行抗病毒治疗将CHB患者分为治疗组(17例)和非治疗组(18例)。Spearman相关分析结果显示,非治疗组血清miRNA-122相对表达量与乙型肝炎血清学标志物模式呈正相关(r=0.73,P=0.00),与HBV DNA载量及HBsAg、HBeAg、ALT水平均呈正相关(r值分别为0.69、0.74、0.53、0.48,P<0.05),与年龄呈负相关(r=-0.58,P=0.01)。治疗组血清miRNA-122相对表达量与HBsAg水平呈正相关(r=0.54,P<0.05),血清miRNA-155相对表达量与HBV DNA载量呈负相关(r=-0.54,P<0.05)。根据是否检测到HBV DNA将治疗组CHB患者分为HBV DNA阴性组和HBV DNA阳性组,HBV DNA阳性组血清miRNA-155相对表达量明显低于HBV DNA阴性组(P<0.05)。结论CHB患者血清miRNA-122与乙型肝炎相关指标HBV DNA、HBsAg、HBeAg、ALT密切相关,或可用于评价HBV复制情况和CHB的严重程度;血清miRNA-155与HBV DNA载量密切相关,或可用于预测和评价CHB的疗效。

Objective To analyze the relationship between serum levels of microRNA-122(miRNA-122),microRNA-155(miRNA-155)and viral replication,antiviral therapy and drug resistance gene mutation in patients with chronic hepatitis B(CHB).Methods A total of 24 healthy subjects and 35 patients with CHB were enrolled.Serum levels of miRNA-122,miRNA-155,hepatitis B virus(HBV)DNA load,hepatitis B surface antigen(HBsAg),hepatitis B surface antibody(HBsAb),hepatitis B e antigen(HBeAg),hepatitis B e antibody(HBeAb),hepatitis B core antibody(HBcAb),alanine aminotransferase(ALT),the drug resistance gene mutation of HBV and the genotyping of HBV were determined,and the correlations were analyzed.Results In CHB group,serum level of miRNA-122 was higher,and serum level of miRNA-155 was lower than those in healthy control group(P<0.05).Spearman correlation analysis showed that the relative expression of serum miRNA-122 in CHB patients without antiviral treatment with nucleoside drugs(non-treatment group,18 cases)was positively correlated with the pattern of hepatitis B serological markers(r=0.73,P=0.00),it was positively correlated with HBV DNA load,HBsAg,HBeAg and ALT in non-treatment group(r=0.69,0.74,0.53 and 0.48,respectively,P<0.05),and it was negatively with age(r=-0.58,P=0.01).In treatment group(17 cases),the relative expression of serum miRNA-122 was positively correlated with the level of HBsAg(r=0.54,P<0.05),while the relative expression of serum miRNA-155 was correlated with HBV DNA load(r=-0.54,P<0.05).CHB group was subclassified into HBV DNA negative group and HBV DNA positive group according to whether HBV DNA was detemined or not.The relative expression of serum miRNA-155 in HBV DNA positive group was lower than that in HBV DNA negative group(P<0.05).Conclusions Serum miRNA-122 is correlated with HBV DNA load,HBsAg,HBeAg and ALT,and it may predict viral replication and severity of CHB.Serum miRNA-155 may be valuable in predicting and evaluating the therapeutic effect of CHB.